Inozyme Pharma, Inc. (INZY)

NASDAQ: INZY · IEX Real-Time Price · USD
5.13
+0.17 (3.43%)
Jul 7, 2022 12:14 PM EDT - Market open
3.43%
Market Cap 205.70M
Revenue (ttm) n/a
Net Income (ttm) -62.46M
Shares Out 40.10M
EPS (ttm) -2.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 18,471
Open 4.98
Previous Close 4.96
Day's Range 4.97 - 5.26
52-Week Range 3.15 - 19.58
Beta n/a
Analysts Buy
Price Target 21.08 (+310.9%)
Earnings Date Aug 10, 2022

About INZY

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is he... [Read more...]

Industry Biotechnology
IPO Date Jul 24, 2020
Employees 50
Stock Exchange NASDAQ
Ticker Symbol INZY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for INZY stock is "Buy." The 12-month stock price forecast is 21.08, which is an increase of 310.92% from the latest price.

Price Target
$21.08
(310.92% upside)
Analyst Consensus: Buy
Stock Forecasts

News

How Much Upside is Left in Inozyme Pharma, Inc. (INZY)? Wall Street Analysts Think 309%

The consensus price target hints at a 308.5% upside potential for Inozyme Pharma, Inc. (INZY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

Inozyme Pharma Announces Partnership with Rady Children's Institute for Genomic Medicine to Advance Newborn Screening...

New technology aims to expand testing to approximately 1,000 diseases and sequencing to 3.7 million newborns annually New technology aims to expand testing to approximately 1,000 diseases and sequencing...

Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer

BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineral...

Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineral...

Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights

– Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency –

Inozyme Pharma to Present at Upcoming Investor Conferences

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today...

Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market

BOSTON, April 14, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal minera...

Inozyme Pharma Starts Dosing In INZ-701 Trial For Calcification Disorders

Inozyme Pharma Inc (NASDAQ: INZY) has dosed the first patient in its Phase 1/2 trial of INZ-701 in adult patients with ABCC6 Deficiency. Also, the second cohort in the ongoing Phase 1/2 clinical trial i...

Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency

- First patient dosed in Phase 1/2 clinical trial in ABCC6 Deficiency –

Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference

BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, tod...

Why Inozyme Pharma Shares Are Jumping Today

Inozyme Pharma Inc (NASDAQ: INZY) announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in the Phase 1 portion of its Phase 1/2 trial of INZ-701 in...

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 De...

- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) levels observed in all three patients in lowest dose cohort (0.2 mg/kg) –

Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights

– Phase 1/2 trial of INZ-701 in adult patients with ENPP1 Deficiency underway –

Inozyme Pharma Strengthens Management Team with Two Executive Appointments

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal minera...

Inozyme Pharma to Present at Cowen 42nd Annual Health Care Conference

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, tod...

Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 D...

- Preliminary biomarker and safety data expected in the first half of 2022 - - Preliminary biomarker and safety data expected in the first half of 2022 -

Wall Street Analysts Believe Inozyme Pharma, Inc. (INZY) Could Rally 257%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 256.5% in Inozyme Pharma, Inc. (INZY). While the effectiveness of this highly sought-after metric is questionable...

Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual Meeting

- Natural History Study shows ectopic calcification and/or cardiovascular disease could serve as distinguishing characteristics of ENPP1 Deficiency in some children with rickets -

Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference

BOSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mi...

Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights

- Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency –

Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today ...

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of A...

INZ-701 was previously granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for ENPP1 Deficiency INZ-701 was previously granted Orphan Drug Designation ...

Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human Resources

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today ...

Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ...

- Clinical trial initiation expected in mid-2021 – - Preliminary safety and biomarker data expected by the end of 2021 -

Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights

– Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe; on track to initiate Phase 1/2 clinical trial in mid-2021 –